Trump, 9 İlaç Şirketi ile İlaç Fiyatlandırma Anlaşmalarını Genişleterek Toplamı 26 'ya Çıkardı — RFK Jr. Başkanla'Çok, Çok Duygusal' Konuşmaların Detayları

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

Namrata Sen

Thu, September 3, 2026 at 1:00 AM GMT+3 4 min read

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices.

The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals Industries Ltd. and UCB.

The agreements, announced on Monday, require the companies to offer discounts on outpatient drugs across all state Medicaid programs, bringing U.S. drug prices more in line with prices in foreign markets. The deals cover treatments for several chronic and rare conditions, including hemophilia, liver disease, skin disorders and certain cancers.

Don't Miss:

A single bad hire can set a startup back years. Here are the 5 hires founders most often misjudge — and why
Still Learning the Market? These 50 Must-Know Terms Can Help You Catch Up Fast

Moreover, the companies have committed to collectively investing at least $19.6 billion in U.S. manufacturing in the near term. Astellas, Sun Pharma, Teva, and UCB have also agreed to donate active pharmaceutical ingredients (API) for key medicines to the federal government's strategic reserve.

26 Drugmakers Now Part of Trump Deals

These new agreements expand the Trump administration's total number of drug pricing deals to 26 companies, which, according to the President, represent 90% of the domestic pharmaceutical market. He said the remaining 10% of the industry is "also coming in" and "has no choice."

Over the past year, the Trump administration has struck drug pricing agreements with 17 other pharmaceutical companies, including Pfizer Inc., Eli Lilly And Co and Novo Nordisk A/S, as part of its "most favored nation" policy.

Secretary of Health and Human Services, Robert F. Kennedy Jr. said, "President Trump…called me and (Dr. Mehmet) Oz every hour of the day and made it very clear that our jobs were dependent on this getting through."

"They were very, very emotional conversations," he added after Trump responded that he wouldn't have fired RFK Jr.

Lower Prices Put Pressure on Pharma

Drugmakers are investing billions to shift manufacturing to the U.S. and expanding direct-to-consumer sales through platforms like TrumpRx to reduce exposure to tariffs. However, lower U.S. drug prices are pressuring revenues, with companies like Novo Nordisk expecting higher prescription volumes to take time to offset the decline.

In May, White House economists estimated that Trump's drug pricing deals could lead to savings of $529 billion over the next decade. The federal and state governments could also collectively save $64.3 billion on Medicaid due to Trump's "most favored nation" policy on drug prices.

Photo courtesy: Shutterstock

Read Next: Think you're saving enough for your kids? You might be dangerously off — see why

Building Wealth Across More Than Just the Market

Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn't tied to the fortunes of just one company or industry.

Arrived

Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100. This allows everyday investors to diversify into real estate, collect rental income, and build long-term wealth without needing to manage properties directly.

Qnetic

As electricity demand rises alongside AI, data centers, and renewable energy, long-duration energy storage is becoming increasingly important. Qnetic is developing a kinetic energy storage system designed to provide long-lasting, chemical-free electricity storage, offering investors exposure to the infrastructure supporting a more resilient and reliable power grid.

EquityMultiple

For accredited investors looking beyond stocks and bonds, EquityMultiple provides access to vetted commercial real estate deals starting at $5,000, with only ~5% of opportunities passing their due diligence process.

FarmTogether

Farmland has historically held its value through market volatility and delivered returns uncorrelated to stocks and bonds. For accredited investors, FarmTogether offers direct access to high-quality U.S. farmland starting at $15,000 — fully managed, with no landlord headaches.

Fundrise

Private real estate and private credit can add income and stability to a stock-heavy portfolio. Fundrise offers access to diversified private real estate and credit strategies through an easy-to-use platform, with professionally managed portfolios designed to generate passive income and long-term growth.